Azitra, Inc. has advanced to Cohort 2 in its ATR-04 Phase 1/2 clinical trial, addressing skin rashes caused by cancer treatments with positive safety data.

The EGFR inhibitors market shows promising forecasts with a 7.9% CAGR from 2026-2036, fueled by the launch of innovative therapies and rising adoption.

ChemDiv unveils upgraded designs and synthesis for reversible pan-EGFR inhibitors targeting lung cancer, enhancing efficacy and safety.

Hoth Therapeutics has announced promising interim findings for HT-001, a first-in-class topical therapy for skin toxicities caused by EGFR inhibitors in cancer treatment.

Azitra, Inc. announces an abstract acceptance for ATR-04-484 clinical trial update at ASCO 2025. They aim to educate oncology professionals about treating EGFR inhibitor-associated rash.

Hoth Therapeutics reports promising interim results from its Phase 2a trial of HT-001, showing significant improvement in pruritus for cancer patients after 21 days of treatment.

Lutris Pharma is set to present findings from a Phase 2 study of LUT014, a topical treatment aimed at combating skin side effects common with anti-cancer therapies, at AACR 2025.

Lutris Pharma announces a $30 million funding round aimed at enhancing the development of an innovative treatment for skin toxicity in cancer therapy, promising better patient outcomes.